SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Nicolas Girard

Nicolas Girard

Institut Curie, Paris

Prof. Nicolas Girard is Head of the Curie-Montsouris Thorax Institute and Chair of the Medical Oncology Department at Institut Curie, Paris, and Professor of Respiratory Medicine at Versailles Saint-Quentin University (Paris-Saclay). He specialises in thoracic oncology, with research spanning perioperative strategies in resectable NSCLC, oncogene-addicted disease (notably EGFR-mutant NSCLC), and rare thoracic tumours such as thymomas; he has been a key investigator on trials including CheckMate-816, TROPION-Lung01, and COCOON. He is a past president of the International Thymic Malignancy Interest Group (ITMIG) and EURACAN domain leader for rare thoracic cancers, and is a frequent speaker at major international congresses.

Connect

Nicolas Girard

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates